Drug Price Transparency Act of 2023

Bill 118 s 1131, also known as the Drug Price Transparency Act of 2023, is a piece of legislation introduced in the US Congress with the aim of increasing transparency in the pricing of prescription drugs. The bill seeks to address the rising costs of prescription medications by requiring drug manufacturers to provide detailed information on the factors that contribute to the pricing of their products.

Under the provisions of the bill, drug manufacturers would be required to disclose the costs of research and development, production, marketing, and advertising for each prescription drug they produce. This information would be made publicly available on a centralized website maintained by the Department of Health and Human Services, allowing consumers, healthcare providers, and policymakers to better understand the pricing of prescription drugs.

In addition to requiring drug manufacturers to disclose pricing information, the Drug Price Transparency Act of 2023 also includes provisions aimed at increasing competition in the pharmaceutical industry. The bill would require drug manufacturers to provide advance notice of price increases for certain prescription drugs, giving consumers and healthcare providers the opportunity to plan for potential cost increases. Overall, the goal of Bill 118 s 1131 is to increase transparency in the pricing of prescription drugs and promote competition in the pharmaceutical industry in order to lower costs for consumers. The bill has garnered bipartisan support in Congress and is currently being considered by relevant committees for further review and potential passage into law.